Saturday 17 October 2026
Export VRCA’s income statement to Excel — free account
Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.54
0.24
−6.35%
Follow VRCA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.30 | 3.03 | 2.49 | 1.33 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.05) | (12.30) | (19.28) | 4.22 | |
P/B ratio |
30.27 | 7.02 | 3.58 | 0.00 | |
Price to Tangible BV |
30.27 | 7.02 | 3.58 | 0.00 | |
EV/Sales |
4.37 | 2.83 | 2.01 | 1.77 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.92) | (7.45) | (4.05) | (1.87) | |
EV/FCF |
(9.74) | (7.32) | (4.00) | (1.86) | |
Quick Ratio |
0.99 | 1.75 | 2.16 | 0.98 | |
Current Ratio |
1.45 | 2.10 | 2.59 | 1.25 | |
Net Debt/EBITDA |
0.81 | 2.11 | 4.21 | 7.51 | |
Debt/Assets |
2.20% | 1.41% | 1.36% | 84.86% | |
Debt/Equity |
0.18 | 0.03 | 0.03 | (2.04) | |
Asset Turnover |
0.81 | 0.92 | 0.70 | 0.84 | |
Operating CF/Net income |
0.71 | 0.95 | 0.57 | (35.35) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(79.86) | (60.72) | (5.47) | 0.78 | |
Research and Development Expense of Revenue |
102.93% | 76.85% | 49.49% | 15.37% | |
Selling, General and Administrative Expense of Revenue |
176.54% | 198.87% | 159.41% | 65.55% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.69% | 17.86% | 13.47% | 5.01% | |
Graham Net Nets |
0.01 | 0.10 | 0.23 | (0.53) | |
Graham Number |
0.00 | 0.00 | 0.00 | 11.74 | |
Earnings Yield |
(27.29%) | (19.47%) | (19.01%) | (79.12%) | |
Free Cash Flow Yield |
(10.43%) | (12.74%) | (20.19%) | (71.75%) | |
Revenue per Share |
0.28 | 0.24 | 0.48 | 1.51 | |
Operating CF per Share |
(0.44) | (0.43) | (0.43) | 1.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.44) | (0.43) | (0.43) | 1.02 | |
Cash per Share |
0.53 | 0.97 | 2.83 | 2.22 | |
Shareholders Equity per Share |
0.20 | 0.75 | 2.32 | (1.80) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.20 | 0.75 | 2.32 | (1.80) | |
Free Cash Flow |
(9.28) | (9.16) | (4.59) | 9.69 | |
Working Capital |
10.20 | 17.91 | 26.10 | 7.37 | |
Net Current Asset Value |
0.93 | 11.40 | 20.15 | (21.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.23 | 6.73 | 2.74 | 3.71 | |
Average Payables |
1.96 | 1.82 | 1.98 | 1.28 | |
Average Inventory |
2.62 | 2.22 | 2.35 | 2.44 | |
Average Assets |
37.56 | 40.48 | 50.63 | 36.91 | |
Average Common Equity |
(6.59) | (1.26) | 7.44 | (25.55) |
Columns are period end dates